Author

Tom Morris

Observed name: TOM MORRIS

Institution: Medivir (Sweden)

Observed institutions: AstraZeneca (United Kingdom), University of Copenhagen, European Organisation for Research and Treatment of Cancer, Medical College of Wisconsin, Oulu University Hospital, Stavanger University Hospital, Sahlgrenska University Hospital, Herlev Hospital, Erasmus MC, Rigshospitalet, Medivir (Sweden), St Olav's University Hospital, European Organisation for Research and Treatment of Cancer, Tampere University Hospital, Transnational University Limburg, Örebro University Hospital, Technische Universität Dresden

OpenAlex ID: A5111414751

Bicalutamide 150 Mg in Addition to Standard Care in Patients With Localized or Locally Advanced Prostate Cancer: Results From the Second Analysis of the Early Prostate Cancer Program at Median Followup of 5.4 Years

2004 · MANFRED P. WIRTH, WILLIAM A. SEE, et al. · The Journal of Urology · 209

Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

2005 · Laurence Collette, Tomasz Burzykowski, et al. · Journal of Clinical Oncology · 113

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia

2004 · Christopher J. Tyrrell, Heather Payne, et al. · International Journal of Radiation Oncology*Biology*Physics · 99

Bicalutamide (150 Mg) Versus Placebo as Immediate Therapy Alone or as Adjuvant to Therapy With Curative Intent for Early Nonmetastatic Prostate Cancer: 5.3-year Median Followup From the Scandinavian Prostate Cancer Group Study Number 6

2004 · PETER IVERSEN, JAN-ERIK JOHANSSON, et al. · The Journal of Urology · 97

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

2004 · Peter Iversen, Manfred P Wirth, et al. · Urology · 18

A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases

2024 · Ruth Plummer, Alastair Greystoke, et al. · Journal of Hepatocellular Carcinoma · 4

Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.

2021 · T.R. Jeffry Evans, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 2

674: The Bicalutamide Early Prostate Cancer Program: Findings of the North American Trial at Median 5.7 Years' Follow-Up

2005 · David G. McLeod, William A. See, et al. · The Journal of Urology · 1

Works count: 8

Citation count: 543

H-index: 5

I10-index: 5